Skip to main content

CASE REPORT article

Front. Oncol.

Sec. Neuro-Oncology and Neurosurgical Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1477978

This article is part of the Research Topic Advances in Brain Tumor Therapy View all 11 articles

Case Report: Rare Intraventricular H3 K27-Altered Diffuse Midline Glioma in an Adult

Provisionally accepted
  • McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas, United States

The final, formatted version of the article will be published soon.

    H3 K27-Altered Diffuse Midline Gliomas are commonly found in children and adolescents in midline locations such as the thalamus, brain stem, and spinal cord. It is rare for these tumors to affect adults and to occur in locations like the lateral ventricles. Despite aggressive treatment methodologies, there is no cure for this disease. The median survival is between 8-12 months.A 24-year-old white male presented to the emergency department due to severe headache refractory to pain medications with a 2-month history of progressive headaches and eventual memory problems. Computed tomography (CT) and magnetic resonance imaging (MRI) showed an intraventricular enhancing mass and hydrocephalus. The final diagnosis was an intraventricular H3 K27-Altered Diffuse Midline Glioma. The patient underwent two craniotomies, one laser interstitial thermal ablation (LITT), chemoradiotherapy, and bevacizumab and ONC206, through compassionate use. Despite a reduction in the tumor size, it continued to spread to other brain areas, leading to further complications and, eventually, his death, 10 months after initial diagnosis.From the review literature, 21 cases were identified, and the median age was 24. Their median survival is 10.5 months (ranges 1 -24 months). This case report presents the clinical, radiological, pathological, and molecular characteristics of a 24-year-old white man diagnosed with a ventricular H3 K27-Altered diffuse midline glioma, highlighting the rare presentation, management, and outcomes.

    Keywords: Diffuse midline glioma (DMG), Diffuse midline glioma H3 K27-altered, Adult DMG, H3 K27, H3K27M mutation

    Received: 08 Aug 2024; Accepted: 18 Feb 2025.

    Copyright: © 2025 Jasso, Zhu and Hergenroeder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Merari Jasso, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, 77030, Texas, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more